ProCE Banner Activity

Phase II DEBBRAH: Trastuzumab Deruxtecan in Cohort With HER2+/HER-Low ABC and Leptomeningeal Carcinomatosis

Conference Coverage

This analysis of a small cohort from the phase II DEBBRAH trial met its primary endpoint of overall survival in patients with HER2-positive or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis treated with trastuzumab deruxtecan.

Released: December 09, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.